Listing Indication Does Not Absolve Aton From Off-Label Examples In Mephyton Slides, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Valeant division was cited for broadening the indication for the oral vitamin K product by presenting examples outside the label and for supporting claims with a meta-analysis.
You may also be interested in...
Valeant Racks Up FDA Letters Criticizing Its Promotional Materials
FDA says Valiant’s webpage for Zovirax overstates the efficacy of the herpes drug and makes unsubstantiated claims it is superior to Valtrex. It is the fifth letter the agency has sent the company in the past year.
Walk Back Those Walking Claims, FDA Tells Acorda And Valeant
In separate “notice of violation” letters sent the same day to Acorda and Valeant, FDA stresses the limits of what companies can do with patient testimonials in web videos.
Valeant Pharmaceuticals To Buy Aton For $318 Mil.; Bolsters U.S. Specialty Business
Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.